Research Update

ReNeuron Group plc
29 June 2006


ReNeuron to present new safety data regarding its stem cell expansion technology
and its ReN001 stem cell line for stroke


Guildford, UK, 29 June 2006: ReNeuron Group plc (LSE: RENE) today announces that
it will be presenting significant new data concerning both its c-mycERTAM stem
cell expansion technology and its ReN001 stem cell line for stroke at leading
international stem cell and neuroscience conferences.

ReNeuron's c-mycERTAM expansion technology is activated by the presence of a
chemical safety switch, 4-hydroxy tamoxifen (4-OHT), which is added to the stem
cell growth medium to initiate cell division whilst maintaining the genetic
stability of the cells.  Removal of 4-OHT will arrest cell division prior to
transplantation of the cells.  These new results show that the c-mycERTAM
transgene is highly specific to 4-OHT and will not be switched on
inappropriately by other related ligands that might be present in a clinical
setting such as the drug, tamoxifen, and naturally occurring steroids and
hormones such as estradiol, progesterone and testosterone.

These findings represent a significant addition to the overall safety profile of
ReNeuron's c-mycERTAM technology platform in terms of its potential to generate
stem cell lines appropriate for therapeutic use.  The presentation of these
findings is one of three poster presentations that ReNeuron will make at the 4th
Annual Meeting of the International Society for Stem Cell Research in Toronto,
Canada on 29 June to I July 2006.

Separately, ReNeuron has demonstrated that its ReN001 stem cell line for stroke
will survive in pre-clinical rodent models regardless of whether an
anti-inflammatory or immunosuppressant drug regimen is used in conjunction with
the transplantation of the cells.   This finding further demonstrates the
potential utility of ReN001 as a cell-based therapeutic agent where these
adjunctive therapies may be required.  ReNeuron is presenting these findings at
the FENS 5th Forum of European Neuroscience meeting in Vienna, Austria, on 8 -12
July 2006.

Commenting on the announcement, Dr John Sinden, Chief Scientific Officer of
ReNeuron, said:

 'These new findings further illustrate the robustness and significant safety
characteristics of our cell expansion technology and the ReN001cell line
developed from it.  We have already developed a broad safety and efficacy data
package for ReN001 and the c-mycERTAM cell expansion platform.  These further
findings will serve to enhance this data package ahead of the clinical trial
application for ReN001 in stroke which we intend to file later this year.'


Enquiries:

ReNeuron
Michael Hunt, CEO                                    Tel: [phone]
John Sinden, CSO

Financial Dynamics
David Yates                                          Tel: [phone]
Sarah Macleod


Notes to Editors

ReNeuron is a leading, UK-based adult stem cell therapy business.  The Group is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.

ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch.  Cell growth can therefore be completely arrested prior to in vivo
implantation.

The Group's lead stem cell therapy, ReN001 for chronic stroke disability, is in
late pre-clinical development.  Subject to successful completion of pre-clinical
testing, the Company plans to file for approval to commence initial clinical
trials in stroke by the end of 2006, with trials commencing as soon as possible
thereafter.

The Group has also generated pre-clinical efficacy data with its ReN005 stem
cell therapy for Huntington's disease, a rare, genetic and fatal
neurodegenerative disorder that affects around 1 in 10,000 people.  This
programme is in pre-clinical development.

In addition to its stroke and Huntington's disease programmes, ReNeuron is
developing stem cell therapies for Parkinson's disease, Type 1 diabetes and
diseases of the retina.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell range of cell lines for use in drug discovery applications
in the pharmaceutical industry.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.

Further information on ReNeuron and its products can be found at
www.reneuron.com.

This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.


                      This information is provided by RNS
            The company news service from the London Stock Exchange              ASMSEDM